Urology News

Urology

Delays in Cancer Surgery Due to COVID-19 Could Harm Survival

Publish Date May 27, 2020

Per-patient delay of 3 or 6 months would result in an estimated 92,214 or 208,275 life-years lost.

Kidney Cancer

Patient Age, Use of Checkpoint Inhibitors in Cancer Linked to COVID-19 Severity

Publish Date May 26, 2020

Cancer is among the underlying conditions that increase risk for COVID-19.

Prostate Cancer

HSD3B1 Genotype Tied to Worse Outcomes in Low-Volume mCSPC

Publish Date May 25, 2020

New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.

Urology

28 Million-Plus Surgeries Could Be Canceled Due to COVID-19

Publish Date May 25, 2020

About 45 weeks needed to clear surgery backlog if countries up surgical volume by 20% later.

Prostate Cancer

Local-Stage Prostate Cancer Incidence Rates Continue to Drop

Publish Date May 22, 2020

Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.

Prostate Cancer

Olaparib Approved for Metastatic Castration-Resistant Prostate Cancer

Publish Date May 21, 2020

The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

Prostate Cancer

ADT May Decrease Risk of COVID-19 in Men With Prostate Cancer, Study Finds

Publish Date May 21, 2020

TMPRSS2, a serine protease expressed in prostate and lung tissue that is necessary for SARS-CoV-2 viral infectivity of host cells, is activated by the androgen receptor.

Urology

Opioid-Related Deaths Less Likely Among Cancer Patients

Publish Date May 15, 2020

Mortality lower despite common opioid prescriptions for cancer-related pain.

Prostate Cancer

PARP Inhibitor Approved for BRCA-Mutated mCRPC

Publish Date May 19, 2020

FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.

Urology

COVID-19 Pandemic Slowing Cancer Research

Publish Date May 19, 2020

Findings based on survey of American Cancer Society research grantees.